Psoriasis Treatment Market Market Analysis

In the past few years, the European psoriasis treatment landscape has undergone notable transformation driven by a series of regulatory milestones and clinical insights that reflect both recent medical history and current evolution. In 2023 the European Commission approved Sotyktu (deucravacitinib), an oral TYK2 inhibitor from Bristol Myers-Squibb, marking the first new mechanism-of-action oral option for moderate-to-severe plaque psoriasis in nearly a decade and prompting shifts in prescribing preferences toward non-injectable systemic therapy that gained traction in Germany and the United Kingdom. Around the same period, bimekizumab (BIMZELX) from UCB received EU approval, distinguished by its dual inhibition of IL-17A and IL-17F and supported by four-year sustained remission data presented at the European Academy of Dermatology and Venereology (EADV) 2024 congress that underscored durability of response in patients previously unresponsive to established biologics. In late 2025, TREMFYA (guselkumab) achieved an expanded European Commission authorization extending its use to children aged six and older the first paediatric indication for an IL-23 inhibitor in plaque psoriasis highlighting a growing focus on earlier-life disease management. Alongside biologic innovation, Europe has seen the launch of biosimilars such as Sandoz’s ustekinumab biosimilar Pyzchiva, broadening access while influencing therapeutic decision-making in national formularies across France, Italy and the Netherlands. At the regulatory level, initiatives by the European Medicines Agency continue to integrate real-world evidence into post-marketing surveillance frameworks, reinforcing safety monitoring across member states and shaping how clinicians balance long-term disease control with emerging treatment choices. According to the research report, "Europe Psoriasis Treatment Market Research Report, 2031," published by Actual Market Research, the Europe Psoriasis Treatment market is expected to reach a market size of USD 13.68 Billion by 2031.Recent developments in the European psoriasis treatment environment illustrate both competitive momentum and strategic refinement across the industry. UCB strengthened its market role with bimekizumab’s expanded evidence base, reporting that patients achieving high-level skin clearance maintained these results up to four years in key European cohorts, and regulatory clearance amassing new indications in psoriatic arthritis and axial spondyloarthritis, broadening its utility beyond skin symptoms. Bristol Myers-Squibb’s Sotyktu reshaped treatment dynamics by offering a once-daily oral alternative that challenged entrenched injectable options and stimulated discussion among dermatologists in major European cities over tailoring therapy to patient lifestyle preferences. Johnson & Johnson’s IL-23-targeted portfolio saw strategic momentum with the European Commission’s approval of TREMFYA (guselkumab) for paediatric plaque psoriasis, marking a historical extension of biologic use into younger age groups and influencing treatment algorithms in pediatric dermatology centers in Spain and Scandinavia.

Parallel to these branded innovations, the introduction of Pyzchiva, an ustekinumab biosimilar marketed by Sandoz in partnership with Samsung Bioepis, reshaped competitive pressure by providing clinicians with a more cost-efficient alternative to the reference IL-12/23 inhibitor, fueling biosimilar adoption in countries with budget-constrained public health systems like Portugal and Greece. Clinical dialogues at recent EADV and national dermatology congresses increasingly emphasize long-term disease management, integration of registry-driven outcomes in practice and sequencing strategies across multiple biologic classes, reflecting a market that is not only technologically advancing but also becoming more evidence-informed and patient-centric. .

Market Dynamic

Psoriasis Treatment MarketSegmentation

Plaque psoriasis remains the fastest-growing type in the European psoriasis treatment market due to its higher prevalence and greater impact on patients' quality of life.

Plaque psoriasis, characterized by thick, red, scaly patches of skin, accounts for the majority of psoriasis cases in Europe, making it a focal point for treatment innovation. The condition's chronic nature and significant impact on daily life drive an increased demand for both novel therapies and traditional treatment options. As the most commonly diagnosed form of psoriasis, plaque psoriasis affects approximately 1-3% of the European population, with varying degrees of severity. This high prevalence makes it a major target for pharmaceutical development, particularly in terms of biologic therapies and oral systemic treatments. The consistent need for treatment regimens that manage both the physical symptoms and psychological burden of the condition has accelerated the introduction of advanced biologics, topical agents, and combination therapies. Moreover, the prevalence of plaque psoriasis is expected to grow as awareness increases, leading to better diagnosis rates across Europe. Countries such as the UK, Germany, and France, with strong healthcare infrastructures, focus much of their clinical research on plaque psoriasis, contributing to the development of more refined treatment pathways. The disease’s visibility in terms of skin lesions often results in earlier diagnosis, further increasing demand for effective long-term management solutions. In parallel, patient advocacy groups in Europe have been instrumental in raising awareness about the chronic, disabling nature of plaque psoriasis, leading to more funding and attention toward therapeutic options. This combination of high prevalence, patient need, and continued advancements in treatment options makes plaque psoriasis a central and rapidly evolving area in the European psoriasis treatment market.

Corticosteroids remain significant in the European psoriasis treatment market because of their long-established effectiveness and wide accessibility as first-line treatments.

Corticosteroids have been a cornerstone in psoriasis management for decades, and despite the advent of biologics and other advanced therapies, they continue to hold a central position in Europe’s treatment protocols. These drugs are typically used for their rapid onset of action, offering relief from the inflammation and scaling associated with psoriasis. Their widespread availability, cost-effectiveness, and ability to be administered in various forms, such as topical creams, ointments, and lotions, make corticosteroids highly accessible for both patients and healthcare systems. In many European countries, corticosteroids are considered first-line treatments for mild to moderate psoriasis and are prescribed regularly by dermatologists in both private and public healthcare settings. Their ability to reduce the symptoms of psoriasis quickly and effectively means they are often used as part of combination therapy, especially for managing flare-ups. Additionally, corticosteroids are crucial in the management of more localized cases of psoriasis, where systemic treatments may not be necessary. Their continued use is supported by extensive clinical experience and a large body of evidence highlighting their efficacy in reducing the severity of psoriasis plaques. While concerns about long-term side effects, such as skin thinning, limit their use in some chronic cases, corticosteroids remain indispensable in both acute flare management and ongoing maintenance. The continued relevance of corticosteroids, combined with their widespread use in clinical practice, solidifies their position as a significant drug class in the European psoriasis treatment market.

Topical drugs remain a key treatment type in the European psoriasis market due to their direct action on the skin, ease of application, and relatively low cost.

Topical treatments, which include corticosteroids, vitamin D analogues, and topical retinoids, are the most commonly used therapies for mild to moderate psoriasis in Europe. These drugs offer targeted treatment directly at the site of the psoriasis plaques, making them particularly effective for managing localized flare-ups. The simplicity of topical treatments, combined with their accessibility and relatively low cost compared to systemic therapies, makes them a preferred option for many patients and healthcare providers. These products are often the first step in managing psoriasis before considering more intensive therapies. The European healthcare system continues to prioritize topical treatments as a cost-effective solution, particularly in public health settings where budget constraints exist. Patients also tend to prefer topical treatments due to their ease of use, allowing for self-management of the disease. These treatments are often used in combination with other therapeutic modalities, including phototherapy and biologic drugs, to manage disease progression more effectively. In addition, topical treatments generally have fewer systemic side effects than oral or injectable therapies, making them an attractive choice for patients who are concerned about potential adverse effects. The ongoing development of new formulations, such as those with improved skin penetration or novel delivery systems, is expected to further strengthen the role of topical drugs in managing psoriasis in Europe. Their effectiveness, affordability, and patient compliance make topical drugs a cornerstone of the European psoriasis treatment market.

Injectable therapies are the largest mode of administration in the European psoriasis treatment market because they offer sustained efficacy and convenience for severe cases of psoriasis.

Injectable therapies, including biologic agents like secukinumab, guselkumab, and adalimumab, have revolutionized the treatment of moderate to severe psoriasis in Europe. These treatments are particularly advantageous for patients who do not respond to topical treatments or phototherapy. The primary appeal of injectable therapies lies in their ability to provide sustained efficacy, with patients often achieving long-term disease remission. The availability of both subcutaneous and intravenous formulations allows flexibility in treatment schedules, and many injectable biologics require less frequent administration after the initial loading phase, making them convenient for patients who prefer fewer clinic visits. These biologic drugs target specific components of the immune system, such as interleukins and tumor necrosis factors, which play a key role in the inflammatory process that causes psoriasis. This targeted approach not only leads to better skin clearance but also improves patients' quality of life by reducing the physical and psychological impact of the disease. The strong efficacy profile and the ability to maintain long-term disease control without the need for daily or frequent treatment make injectables the preferred choice for many healthcare providers managing severe cases. The European market’s infrastructure supports the wide adoption of injectables, with countries like Germany and France offering comprehensive reimbursement for biologics, ensuring that patients have access to these advanced treatments. As new biologics continue to be approved and more options become available, injectable therapies will remain the dominant mode of administration in the European psoriasis treatment market.

e-Commerce is the fastest-growing distribution channel in the European psoriasis treatment market due to its convenience and increased adoption of online healthcare services.

The rise of e-commerce as a distribution channel for psoriasis treatments in Europe is largely driven by the growing demand for convenience and the increasing use of digital health platforms. As patients and caregivers become more comfortable with online shopping for healthcare products, e-commerce platforms are becoming an essential part of the psoriasis treatment landscape. Patients can now easily access a wide range of psoriasis treatment options, including over-the-counter topical treatments, prescription medications, and complementary skincare products, from the comfort of their homes. This trend is particularly noticeable in countries like the UK and the Netherlands, where the digital health ecosystem has matured, and patients have embraced telemedicine for consultations and follow-up care. The convenience of home delivery, the ability to compare prices, and the broader availability of specialized products that may not be available in physical pharmacies are all factors contributing to the growth of e-commerce. Additionally, many e-commerce platforms now offer tailored advice, allowing patients to choose the most suitable treatments based on their specific needs. This trend has been further accelerated by the COVID-19 pandemic, which pushed more patients to seek online solutions as face-to-face interactions with healthcare providers became limited. As healthcare providers and pharmaceutical companies continue to integrate e-commerce solutions with traditional treatment models, the growth of online platforms in the European psoriasis treatment market is set to continue.

Psoriasis Treatment Market Market Regional Insights

Germany is the leading region in the European psoriasis treatment market due to its strong healthcare infrastructure, large patient population, and advanced dermatology research.

Germany has long been a leader in the European healthcare market, and its position as the dominant region for psoriasis treatment is supported by several factors. First, Germany's robust healthcare system offers broad access to advanced dermatological care, including access to biologics and other cutting-edge treatments. The country’s universal healthcare model ensures that patients across different demographics can access the most suitable psoriasis therapies, from topical treatments to biologics. Additionally, Germany is home to some of the most prestigious dermatology research institutions, which continue to drive innovation in psoriasis treatment. The country’s well-established clinical trial network has facilitated the rapid adoption of new therapies, making it a key testing ground for pharmaceutical companies looking to introduce their products to the European market. Moreover, the German healthcare system provides comprehensive insurance coverage, reducing the financial burden on patients and enabling widespread access to advanced treatment options. With a large psoriasis patient population, Germany’s market demand for psoriasis treatments is substantial, further propelling its leadership in the region. Its strong regulatory environment, high levels of patient education, and involvement of dermatologists in shaping treatment guidelines have positioned Germany at the forefront of the European psoriasis treatment market. As a result, the country continues to be a critical player in driving both the availability of treatment options and the adoption of innovative therapies for psoriasis patients.